Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Caffeine acts as a central nervous system stimulant primarily through antagonism of adenosine A1 and A2A receptors. This antagonism reduces adenosine's inhibitory effects on neuronal activity, leading to increased alertness, reduced fatigue, and enhanced cognitive performance. While caffeine primarily targets adenosine receptors, at very high doses, it can also affect calcium mobilization and phosphodiesterase inhibition. However, these effects are less relevant at typical dietary doses.
Antagonism of adenosine A1 and A2A receptors, leading to increased neuronal firing and neurotransmitter release (dopamine, norepinephrine, serotonin, adrenaline).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosine Receptor Antagonism (Caffeine-mediated).